2019
December 14, 2022
|By Megan McGregor
The FDA concluded that Philips’s leadership had discussed foam degradation issues concerning CPAPs, BiPAPs, and Triology ventilators at management review meetings since at least 2019.
The FDA concluded that Philips’s leadership had discussed foam degradation issues concerning CPAPs, BiPAPs, and Triology ventilators at management review meetings since at least 2019.